We are delighted to announce that Allegrow has signed a memorandum of understanding (MOU) with Provectus Therapeutic at ASGH 2026 in Hong Kong, marking the beginning of a strategic partnership to bring novel technologies and cutting‑edge biotechnology research closer to real‑world impact. Together, we aim to decode how engineered immune cells interact with tumours at single‑cell resolution, enabling better therapy design and more precise treatment strategies.
We are grateful for the trust and collaboration from our partners at Provectus Therapeutic, and looking ahead, we plan to co‑develop workflows for researchers and clinicians to advance single‑cell precision oncology and accelerate the development of safer, more effective cell and cancer therapies. This is just the beginning of our journey together.
Researchers, clinicians, and partners interested in AimGel and our collaboration with Provectus Therapeutic are welcome to reach out directly to explore opportunities.
Contact : welovecells@allegrowbiotech.com
Write-up by: Sheri Cheng